Seeking Alpha

SuperSmartStocks'  Instablog

SuperSmartStocks
Send Message
Masters degree from USC. Business Professional. SuperSmartStocks provides quality information to people who want to make $$$.
My company:
SuperSmartStocks
My blog:
SuperSmartStocks
My book:
SuperSmartStocks
  • TTNP Could It Have Giant Gains?? 1 comment
    Oct 6, 2013 2:37 PM

    TTNP / TITAN PHARMACEUTICALS INC.

    As recent history proves, Titan Pharmaceuticals, Inc. (OTC: TTNP) has a long expedient of surprising movements in the market. The company has a current market cap of $77.59M since its start at $47,55M and develops products for the treatment of central nervous system (NYSE:CNS) diseases.

    In recent months TTNP made astonishing movements going from under $1 to highs near $2.50 per share, even when the stock dropped at 1$ but kept still on the move. In 2009, the company made market headlines by running lows of a penny to highs of $2.50 per share so when volume and price started a run investors were ready to take action.

    Visit titanpharm.com for more info

    Did You Know? SuperSmartStocks is the new penny stocks information portal that reports on all active penny stocks. We also have huge stock picks. Subscribe right now to the greatest stock picks newsletters on the planet!

    During september TTNP announced an agreement with Braeburn Pharmaceuticals Sprl for a $15.75M upfront payment in concept of exclusive commercialization of the investigational product Probuphine, a new subdermal implant designed for the treatment of opioid addiction.

    Being that said, the deal sounds good even when they had to wait for the New Drug Application (NDA) to get a chance of review by the U.S. Food and Drug Administration (FDA), same is being classified now as a "Priority Review" by the institution.

    Conclusion:

    Probuphine is the second product TTNP develops after releasing Fanapt® (iloperidone), an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients, their second effort is in Phase 3 and is even giving a priority review status by the U.S. goverment, you make the math. The company is well funded now with a $4M capital infusion and could easily move much higher from current price levels with nothing to fear about.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Themes: Goog
Back To SuperSmartStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • Don-Johnson
    , contributor
    Comments (45) | Send Message
     
    Stock is nearly a no-brainer.. would be a total no-brainer but the FDA can surprise even the best investors among us. Implantation of the drug to curb drug craving symptoms not only helps maintain regular usage but also curbs the selling of the active chemical on the black market for abuse. Every drug abuse center will opt to use this versus prescribing pills.. it is the only logical thing to do when your dealing with drug addicts. The stock goes to $5 easily within a year after approval and quite possibly higher in my view. From what I gather, the FDA did not approve it earlier due to lack of information on procedures for administering the drug. I'm sure Titan has produced what is needed for the FDA and it's now a matter of waiting till the meeting and approval, fingers crossed of course.
    13 Oct 2013, 02:12 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

  • CNR Super Smart Stock pick today blew up !!!!
    Oct 17, 2013
More »

Latest Comments


Most Commented
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.